March 1, 2005
California infomercial producer Modern Interactive Technology, Inc. (MIT), and its two principals have agreed to settle Federal Trade Commission charges that they had an active role in developing the deceptive claims made to sell The Enforma System weight-loss products.
This is the last case growing out of the sales of the Enforma System, a weight-loss product consisting of two dietary supplements Fat Trapper and Exercise In A Bottle.
In April 2000, the FTC announced that it had settled charges against Enforma Natural Products, Inc., the vendor of the Enforma System. The order in that case required Enforma Natural Products and its principal Andrew Grey to pay $10 million in consumer redress.
Then, in August 2000, the FTC filed a complaint in federal district court against MIT and its officers, alleging that they played an active role in writing, editing, and producing the infomercials for the Enforma System.
In September 2001, however, the district court issued an order ruling that the Commission had no right to bring a separate action against the infomercial producers. The Commission appealed this ruling to the Ninth Circuit Court, and in September 2004, the Ninth Circuit reversed the district court.
It held that Enforma Natural Products was not sufficiently connected to MIT and its principals to justify barring the FTCs claims against them, and remanded the matter to the district court for litigation.
The settlement announced today resolves the charges without the need for further court proceedings.
The settlement order:
• requires the defendants to have competent and reliable scientific evidence for claims that any dietary supplement, food, drug, or device causes weight loss or maintenance, prevents fat absorption, or causes increased metabolism or fat- burning claims;
• prevents the defendants from misrepresenting the profession, expertise, training, education, experience, or qualifications of any person who advertises, promotes, or endorses any product, service, or program;
• requires the defendants to have competent and reliable scientific evidence to support any representation about the health or weight-loss benefits, performance, safety, or efficacy of any dietary supplement, food, drug, or device; and
• prohibits the defendants from misrepresenting test results.
The order does not require the defendants to pay consumer redress but contains an avalanche clause for $2 million, the amount the defendants were paid for producing the Enforma infomercials, which will be triggered if they have misrepresented their current financial condition.
